Allogene Therapeutics (ALLO) Revenue (2021 - 2026)

Allogene Therapeutics has reported Revenue for 4 years, with the latest figure at $22000.0 in Q1 2024.

• Quarterly Revenue fell 26.67% year-over-year to $22000.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $22000.0 (down 76.84% YoY) and the FY2024 annual result came in at $22000.0, down 76.84% from the prior year.
• Revenue advanced to $22000.0 in Q1 2024 per ALLO's latest filing, from $21000.0 in the prior quarter.
• Over five years, Revenue peaked at $75.7 million in Q4 2021 and troughed at $21000.0 in Q4 2023.
• A 4-year average of $8.8 million and a median of $30000.0 in 2023 frame the typical range for Revenue.
• The widest YoY moves for Revenue: up 45.45% in 2022, down 99.97% in 2022.
• Over 4 years, Revenue stood at $75.7 million in 2021, then tumbled by 99.97% to $26000.0 in 2022, then dropped by 19.23% to $21000.0 in 2023, then rose by 4.76% to $22000.0 in 2024.
• According to Business Quant data, Revenue over the past three periods registered $22000.0, $21000.0, and $22000.0 for Q1 2024, Q4 2023, and Q3 2023 respectively.